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Abstract
NUP98-HOXA9 is the prototype of a group of oncoproteins associated with acute myeloid leukemia. It consists of an N-
terminal portion of NUP98 fused to the homeodomain of HOXA9 and is believed to act as an aberrant transcription factor
that binds DNA through the homeodomain. Here we show that NUP98-HOXA9 can regulate transcription without binding
to DNA. In order to determine the relative contributions of the NUP98 and HOXA9 portions to the transforming ability of
NUP98-HOXA9, the effects of NUP98-HOXA9 on primary human CD34+ cells were dissected and compared to those of wild-
type HOXA9. In contrast to previous findings in mouse cells, HOXA9 had only mild effects on the differentiation and
proliferation of primary human hematopoietic cells. The ability of NUP98-HOXA9 to disrupt the differentiation of primary
human CD34+ cells was found to depend primarily on the NUP98 portion, whereas induction of long-term proliferation
required both the NUP98 moiety and an intact homeodomain. Using oligonucleotide microarrays in primary human CD34+
cells, a group of genes was identified whose dysregulation by NUP98-HOXA9 is attributable primarily to the NUP98 portion.
These include RAP1A, HEY1, and PTGS2 (COX-2). Their functions may reflect the contribution of the NUP98 moiety of NUP98-
HOXA9 to leukemic transformation. Taken together, these results suggest that the effects of NUP98-HOXA9 on gene
transcription and cell transformation are mediated by at least two distinct mechanisms: one that involves promoter binding
through the homeodomain with direct transcriptional activation, and another that depends predominantly on the NUP98
moiety and does not involve direct DNA binding.
Citation: Yassin ER, Sarma NJ, Abdul-Nabi AM, Dombrowski J, Han Y, et al. (2009) Dissection of the Transformation of Primary Human Hematopoietic Cells by the
Oncogene NUP98-HOXA9. PLoS ONE 4(8): e6719. doi:10.1371/journal.pone.0006719
Editor: Catherine M. Verfaillie, KU Leuven, Belgium
Received April 23, 2009; Accepted July 28, 2009; Published August 21, 2009
Copyright:  2009 Yassin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by National Institutes of Health grants R01 HL082549 and K02 HL084179 (N.R.Y.), and by T32 CA009547 (A.M.A.). The Siteman
Cancer Center is supported in part by an NCI Cancer Center Support Grant #P30 CA91842. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: nyaseen@path.wustl.edu
Introduction
NUP98-HOXA9 is an oncogenic fusion protein associated with
acute myeloid leukemia (AML) that consists of an N-terminal, FG
repeat-rich portion of the nucleoporin NUP98 fused to the
homeodomain region of HOXA9 [1,2]. It is the prototype of
several similar leukemogenic fusions linking NUP98 to one of
several homeodomain-containing transcription factors [3].
NUP98-HOX fusions act as aberrant transcription factors
[4,5,6,7,8,9,10]. They induce proliferation and block differentia-
tion in mouse hematopoietic precursors, and cause leukemia in
mice [9,10,11,12,13,14]. Some of these effects require a functional
homeodomain [4,6,11,12,13]. In human primary hematopoietic
cells, NUP98-HOXA9 induces long-term proliferation and blocks
differentiation [15,16]. It is not known whether these effects are
dependent on homeodomain-DNA binding. Wild-type HOXA9
overexpression is leukemogenic in mice [12]. It induces prolifer-
ation with a differentiation block in mouse hematopoietic cells in
vitro, and these effects are dependent on the presence of a
functional homeodomain [17]. However, the effects of HOXA9
on the proliferation and differentiation of primary human
hematopoietic cells have not been reported.
Several lines of evidence suggest that NUP98-HOXA9 may
have effects over and above those mediated by the homeodomain.
For example, in mice, the leukemia induced by NUP98-HOXA9
is preceded by a myeloproliferative phase whereas leukemia
caused by overexpression of wild-type HOXA9 is not preceded by
myeloproliferation [12]; and the in vitro effects of NUP98-HOXA9
on the differentiation and proliferation of mouse hematopoietic
precursors are more profound than those of HOXA9 [13]. In
addition, NUP98-HOXA9 modulates the expression of a larger set
of genes than HOXA9 in a myeloid cell line [6]. Finally, while all
leukemogenic NUP98 fusions contain an almost identical N-
terminal portion of NUP98, most of them lack a homeodomain
[18], suggesting that homeodomain-independent mechanisms may
contribute to leukemogenesis by NUP98 chimeras.
In a recent study, a mutation that abolishes DNA binding
(N51S) was introduced into the homeodomain of another
leukemogenic NUP98 fusion, NUP98-HOXD13, and its effect
on the gene expression profile in mouse hematopoietic cells was
examined. It was found that the homeodomain mutant was still
capable of dysregulating a subset of the genes dysregulated by
NUP98-HOXD13 [19] indicating that some of the aberrant gene
expression is independent of DNA binding by the homeodomain.
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However, it is not clear whether this homeodomain-independent
dysregulation occurs at the transcriptional level and whether it has
any functional significance in terms of leukemic transformation.
These are among the questions we sought to answer in the current
study. We first introduced the N51S mutation into NUP98-
HOXA9 and showed that the mutant was capable of regulating
transcription in a myeloid cell line without significant binding to
DNA. We then compared this mutant to another mutant lacking
the NUP98 portion as well as to intact NUP98-HOXA9 and wild-
type HOXA9 for their ability to transform primary human
CD34+ hematopoietic precursors. The results show that most of
the effects of NUP98-HOXA9 on differentiation are dependent on
the NUP98 portion and are not abolished by the N51S mutation.
Gene expression profiling in primary human CD34+ cells
identified a subset of the NUP98-HOXA9 target genes whose
dysregulation requires the NUP98 moiety and appears to be
independent of the homeodomain. The possible role of these genes
in the transformation of primary human hematopoietic cells by
NUP98-HOXA9 is discussed.
Results
Two distinct modes of transcriptional regulation by
NUP98-HOXA9
To determine the role of homeodomain-DNA binding in the
regulation of transcription by NUP98-HOXA9, luciferase reporter
assays were carried out using the K562 human myeloid cell line.
This cell line has been used successfully for analyzing transcrip-
tional regulation by NUP98-HOXA9 [6,20]. As the genes that
NUP98-HOXA9 regulates in K562 cells are largely different from
those it regulates in primary human CD34+ cells [6,15], it was
necessary to identify likely transcriptional targets of NUP98-
HOXA9 in K562 cells. A microarray study was first undertaken to
identify genes whose expression is modulated by NUP98-HOXA9
at an early time point (Table S1). The promoters of several of these
genes were subcloned into the pGL4.11 vector upstream of
luciferase. The luciferase reporter constructs were introduced into
K562 cells along with a construct expressing NUP98-HOXA9.
Two of these genes, KBTBD10 and PLN, showed clear
transactivation by NUP98-HOXA9 (Fig. 1).
To determine whether this transactivation is dependent on
homeodomain-DNA binding, the N51S mutation was introduced
into the homeodomain of NUP98-HOXA9 (Fig. 2A). The N51
residue of the homeodomain is very highly conserved among
different homeobox proteins and is involved in direct homeodo-
main-DNA binding [21,22]. Mutation of this residue has been well
characterized and shown to abolish the ability of homeobox
proteins to bind to DNA [10,17,19,23]. The resulting mutant,
NUP98-HOXA9/N51S, was expressed at a level equivalent to
NUP98-HOXA9 in K562 cells (Fig. 2B). NUP98-HOXA9/N51S
was tested for its effects on transcription from the KBTBD10 and
PLN promoters. NUP98-HOXA9/N51S did not transactivate the
KBTBD10 promoter (Fig. 3A); but surprisingly, it was able to
transactivate the PLN promoter to the same extent as NUP98-
HOXA9 (Fig. 3B). This suggests that NUP98-HOXA9 transacti-
vates the PLN promoter by a mechanism that does not involve
direct DNA binding. To confirm this, chromatin immunoprecip-
itation (ChIP) studies were carried out. First, deletion studies of the
KBTBD10 and PLN promoters were used to identify promoter
regions responsible for transactivation by NUP98-HOXA9
(Fig. 4A, 4B, and 5A) and PCR primers were chosen for ChIP
accordingly (Fig. 5A). Flag-tagged versions of NUP98-HOXA9
and NUP98-HOXA9/N51S were introduced into K562 cells by
nucleofection. Chromatin was immunoprecipitated with anti-Flag
antibody and the indicated segments of the KBTBD10 and PLN
promoters were amplified by PCR. NUP98-HOXA9 showed
association with the KBTBD10 promoter whereas NUP98-
HOXA9/N51S did not show significant binding (Fig. 5B). Neither
NUP98-HOXA9 nor NUP98-HOXA9/N51S showed significant
binding to the segment of the PLN promoter that is transactivated
by NUP98-HOXA9 (Fig. 5B). There may be very weak binding of
NUP98-HOXA9 to the segment amplified by the PLN (3) primer
set. However, unlike the binding to the KBTBD10 promoter, this is
difficult to distinguish from background and is not affected by the
N51S mutation. Therefore it is unlikely to represent direct specific
binding of the homeodomain to the promoter, but it could
represent a very weak indirect interaction between NUP98-
HOXA9 and the PLN promoter that is difficult to detect by our
ChIP assays. Overall, the ChIP findings and the results of
luciferase assays (Fig. 3A and 3B) show that transactivation of the
KBTBD10 promoter correlates with DNA binding whereas
transactivation of the PLN promoter does not.
Taken together, these data suggest that NUP98-HOXA9
modulates transcription by at least two mechanisms: one,
exemplified by the KBTBD10 promoter, involves direct binding
to the promoter through the homeodomain; while the other,
exemplified by the PLN promoter, does not involve DNA binding.
Disruption of the differentiation of primary human
CD34+ cells by NUP98-HOXA9 does not require
homeodomain-DNA binding
The data described above showed that NUP98-HOXA9 can
disrupt gene expression by mechanisms that do not require DNA
binding. It was not clear, however, whether such mechanisms
Figure 1. NUP98-HOXA9 regulates gene expression at the
transcriptional level. K562 cells were transfected by electroporation
with either empty pGL4.11 luciferase vector or with vector containing
the promoter region of one of the five indicated genes (KBTBD10, kelch
repeat and BTB (POZ) domain containing 10; PLN, phospholamban;
HOXB6, homeobox B6; SERPINE1, serine proteinase inhibitor E1; and
JUN, v-jun sarcoma virus 17 oncogene homolog) in combination with
either empty pTracer/CMV-Bsd vector (Control) or vector expressing
NUP98-HOXA9. Firefly luciferase activity was measured 48 h after
transfection and normalized to a Renilla luciferase internal control. The
numbers represent fold change over control (average of 3 independent
experiments); error bars represent standard deviation.
doi:10.1371/journal.pone.0006719.g001
Transformation by NUP98-HOXA9
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contribute to leukemic transformation of human primary CD34+
cells by NUP98-HOXA9. We have previously shown that NUP98-
HOXA9 interferes with both erythroid and myeloid differentiation
of primary human CD34+ hematopoietic cells [15]. To determine
the relative contributions of the NUP98 and HOXA9 moieties to
disruption of hematopoietic differentiation of primary human
CD34+ cells by NUP98-HOXA9, retroviral vectors were prepared
that express NUP98-HOXA9, wild-type HOXA9, NUP98-
HOXA9/N51S, and a mutant of NUP98-HOXA9 that lacks
the NUP98 moiety (HOXA9DN) (Fig. 6A). All constructs
expressed comparable protein levels in primary human CD34+
cells (Fig. 6B). The effects of NUP98-HOXA9, NUP98-HOXA9/
N51S, HOXA9, and HOXA9DN on the differentiation of
primary human CD34+ cells were compared to those of empty
vector. Differentiation was assessed by colony-forming cell (CFC)
assays combined with morphologic evaluation and flow cytometric
immunophenotyping.
As previously reported [15], inspection of CFC plates without
magnification showed many prominent large erythroid colonies in
samples expressing NUP98-HOXA9 (Fig. 7). The large colonies
included some with decreased hemoglobinization, indicating
incomplete erythroid maturation. Cells expressing NUP98-
HOXA9/N51S gave rise to a similar macroscopic appearance
but with more fully hemoglobinized erythroid colonies (Fig. 7). In
contrast, cells expressing either HOXA9 or HOXA9DN did not
give rise to macroscopically prominent erythroid colonies (Fig. 7).
To further assess erythroid differentiation, cells were harvested
from the CFC plates and subjected to morphologic evaluation on
Giemsa-stained Cytospin preparations (Fig. 8) and to flow
cytometric immunophenotyping (Fig. 9). The total number of
cells per plate was increased in the NUP98-HOXA9 and the
NUP98-HOXA9/N51S samples but not in the HOXA9 and
HOXA9DN samples (Table 1). A 500-cell differential count was
carried out on the Giemsa-stained slides from each sample; the
average numbers from 3–4 independent experiments are shown in
Table 1 and representative fields are shown in Fig. 8. There was a
marked increase in the numbers of erythroid cells with a shift to
immaturity in the NUP98-HOXA9 sample. Erythroid cells were
also markedly increased in the NUP98-HOXA9/N51S sample,
but without a statistically significant morphologic shift to
immaturity. Erythroid cell number and morphology in the
HOXA9 and HOXA9DN samples were not significantly different
from the control sample.
To evaluate erythroid differentiation by flow cytometry,
erythroid cells were gated based on CD235a (Glycophorin A)
positivity, and plotted on a histogram to show the level of CD235a
expression relative to control cells (Fig. 9A). The expression level of
CD235a was decreased in cells expressing NUP98-HOXA9 and
NUP98-HOXA9/N51S, indicating disrupted erythroid differenti-
ation. In contrast, no significant reduction in CD235a expression
was seen in cells expressing HOXA9 and HOXA9DN.
Myeloid differentiation was also assessed by morphologic
evaluation of Giemsa-stained Cytospin preparations and flow
cytometric immunophenotyping. The results of 500-cell differen-
tial counts are shown in Table 1 and representative fields from the
Giemsa-stained slides are shown in Fig. 8. The percentage of
mature myeloid cells was markedly decreased in the NUP98-
HOXA9 samples, moderately decreased in the NUP98-HOXA9/
N51S samples, and mildly decreased in the HOXA9 samples
(Table 1). Primitive cells were markedly increased in the NUP98-
HOXA9 samples and mildly increased in the HOXA9 samples.
The latter also showed a significant increase in the numbers of
myeloid cells with intermediate differentiation. NUP98-HOXA9/
N51S caused a mild increase in the numbers of primitive cells, but
Figure 2. Expression of the NUP98-HOXA9/N51S mutant in K562 cells. (A) Schematic representation of the N51S mutation in the
homeodomain of HA-tagged NUP98-HOXA9. FG Repeats: NUP98 FG repeat region; HD: HOXA9 homeodomain. (B) Immunoblotting using anti-HA
antibody shows equivalent expression of NUP98-HOXA9 (NH9) and NUP98-HOXA9/N51S (NH9/N51S) in K562 cells.
doi:10.1371/journal.pone.0006719.g002
Transformation by NUP98-HOXA9
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the change did not reach statistical significance. HOXA9DN did
not cause a significant change in myeloid cell morphology.
For flow cytometric evaluation of myeloid differentiation,
myeloid cells (CD33+) were gated and the level of CD11b
expression was compared to control cells on a histogram (Fig. 9B).
Both NUP98-HOXA9 and NUP98-HOXA9/N51S caused a
prominent decrease in the expression of CD11b, consistent with a
block in myeloid differentiation. In contrast, HOXA9 and
HOXA9DN did not significantly alter the expression of CD11b.
The effects of NUP98-HOXA9, NUP98-HOXA9/N51S,
HOXA9, and HOXA9DN on the differentiation of primary
human CD34+ cells are summarized in Table 2. The ability of
NUP98-HOXA9/N51S to recapitulate most of the effects of
NUP98-HOXA9 suggests that the disruption of hematopoietic
differentiation by NUP98-HOXA9 is largely attributable to the
NUP98 moiety and does not require DNA binding by the
homeodomain. The fact that the isolated HOXA9 moiety
(HOXA9DN) had no effect on differentiation shows that the
NUP98 moiety is necessary for disruption of human hematopoietic
differentiation. This is further confirmed by the observation that
wild-type HOXA9 had only a mild effect on differentiation in spite
of containing both the homeodomain and a transactivating
domain.
The two moieties of NUP98-HOXA9 act synergistically to
induce proliferation of primary human CD34+ cells
NUP98-HOXA9 induces long-term proliferation of primary
human CD34+ cells in liquid culture [15,16]. In order to assess the
relative contributions of the NUP98 and HOXA9 moieties to this
proliferative effect, NUP98-HOXA9, NUP98-HOXA9/N51S,
wild-type HOXA9, and HOXA9DN were introduced into
primary human CD34+ hematopoietic cells by retroviral trans-
duction, with empty retroviral vector as a control. Cells expressing
the transduced constructs were selected by sorting for GFP and
were cultured in liquid media with a cytokine cocktail as previously
described [15] with periodic feeding and counting (Fig. 10A). The
different samples showed similar growth profiles for approximately
the first month, after which the numbers of control cells and cells
expressing HOXA9DN began to decline. Cells expressing
HOXA9 or NUP98-HOXA9/N51S showed a modest degree of
growth for another few weeks before beginning to decline as well.
As expected, NUP98-HOXA9 induced a marked increase in the
number of cells in long-term liquid culture that was several orders
of magnitude more than that of control cells.
Long-term proliferation of primary human CD34+ cells in
liquid culture is usually associated with an increase in the numbers
of primitive self-renewing cells. These cells are quantitated by the
long-term culture-initiating cell (LTC-IC) assay [24]. As previously
shown [15], NUP98-HOXA9 induced an increase in the numbers
of LTC-ICs (Fig. 10B). On the other hand, NUP98-HOXA9/
N51S, HOXA9, and HOXA9DN did not cause an increase in the
numbers of LTC-ICs. Although HOXA9 is leukemogenic in mice
[12] and immortalizes primary mouse hematopoietic cells in vitro
[17], our data suggest that it does not have a similar effect on
primary human hematopoietic cells.
The effects of NUP98-HOXA9, NUP98-HOXA9/N51S,
HOXA9, and HOXA9DN on the proliferation of primary human
CD34+ cells are summarized in Table 2. The modest increase in
cell numbers induced by NUP98-HOXA9/N51S and HOXA9 in
long-term culture compared to controls may reflect increased cell
survival with a slight increase in proliferation. The data suggest
that the effect of NUP98-HOXA9 on cell numbers is partially
dependent on classical transactivation involving DNA binding and
partially on mechanisms other than DNA binding. The two
mechanisms appear to act synergistically since the effect of
NUP98-HOXA9 on long-term proliferation and the number of
LTC-ICs is more than the sum of the separate effects of HOXA9
and NUP98-HOXA9/N51S.
Homeodomain-independent gene regulation by NUP98-
HOXA9 in primary human CD34+ cells
The data described above show that disruption of the
differentiation of primary human CD34+ cells by NUP98-
HOXA9 is to a large extent independent of DNA binding by
the homeodomain. To identify changes in gene expression that
underlie this disrupted differentiation, expression microarray
analysis was performed. Primary human CD34+ cells were
transduced with retroviral vectors expressing NUP98-HOXA9,
NUP98-HOXA9/N51S, wild-type HOXA9, and HOXA9DN as
well as control empty vector, and were sorted for GFP expression.
RNA was isolated from the cells and analyzed using the Affymetrix
Figure 3. Transcriptional regulation by NUP98-HOXA9/N51S.
(A) K562 cells were transfected by electroporation with a luciferase
construct driven by the KBTBD10 promoter and either empty pTracer/
CMV-Bsd vector (Control) or vector expressing NUP98-HOXA9 (NH9) or
NUP98-HOXA9/N51S (NH9/N51S). Firefly luciferase activity was mea-
sured 48 h after transfection and normalized to a Renilla luciferase
internal control. The numbers represent fold change over control
(average of 4 independent experiments); error bars represent standard
deviation. (B) K562 cells were transfected by electroporation with a
luciferase construct driven by the PLN promoter and either empty
pTracer/CMV-Bsd vector (Control) or vector expressing NUP98-HOXA9
(NH9) or NUP98-HOXA9/N51S (NH9/N51S). Luciferase activity was
measured and plotted as described in A above.
doi:10.1371/journal.pone.0006719.g003
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Figure 4. Identification of promoter sequences responsible for transactivation by NUP98-HOXA9. (A) The indicated segments of the
KBTBD10 promoter were subcloned into the pGL4.11 plasmid upstream of luciferase (LUC). K562 cells were transfected by electroporation with either
empty pGL4.11 vector or with vector containing the indicated segments of the KBTBD10 promoter along with either empty pTracer/CMV-Bsd vector
(Control) or vector expressing NUP98-HOXA9 (NH9). Luciferase activity was measured and plotted as described in 3A above. The numbers represent
the averages of 3 independent experiments. (B) Identification of PLN promoter sequences responsible for transactivation by NUP98-HOXA9. The
indicated segments of the PLN promoter were subcloned into the pGL4.11 plasmid upstream of luciferase (LUC). K562 cells were transfected by
electroporation with either empty pGL4.11 vector or with vector containing the indicated segments of the PLN promoter along with either empty
pTracer/CMV-Bsd vector (Control) or vector expressing NUP98-HOXA9 (NH9). Luciferase activity was measured and plotted as described in 3A above.
The numbers represent the averages of 3 independent experiments.
doi:10.1371/journal.pone.0006719.g004
Transformation by NUP98-HOXA9
PLoS ONE | www.plosone.org 5 August 2009 | Volume 4 | Issue 8 | e6719
Human genome U133+2.0 array. The experiment was performed
two independent times, and lists of probe sets showing a difference
of 1.74-fold or more compared to control in both experiments
were compiled (Tables S2, S3, S4, S5). As shown in Fig. 11A, 46 of
the probe sets showed dysregulation by both NUP98-HOXA9 and
NUP98-HOXA9/N51S. Some of these overlap probe sets showed
dysregulation by HOXA9 and HOXA9DN (Fig. 11A) suggesting
dysregulation by mechanisms involving homeodomain sequences
(see Discussion). The remaining 26 probe sets represent 23 unique
genes are dysregulated by mechanisms that require the NUP98
moiety but are apparently independent of the homeodomain (see
Discussion). One of these genes, HEY1, is also dysregulated in
K562 cells by retrovirally transduced NUP98-HOXA9 [6]. A
ChIP assay was performed on the HEY1 promoter [25,26] in
K562 cells expressing either NUP98-HOXA9 or its N51S mutant.
As shown in Fig. 11B, neither NUP98-HOXA9 nor its N51S
mutant bound to the HEY1 promoter, supporting the notion that
its transactivation is independent of direct homeodomain-DNA
interaction. Among the genes listed in Fig. 11A, a few are notable
for functions that may explain the transforming activities shared by
NUP98-HOXA9 and NUP98-HOXA9/N51S:
RAP1A. This gene was downregulated by NUP98-HOXA9
and NUP98-HOXA9/N51S. It encodes a small GTPase of the
Ras family that was identified as a suppressor of the transforming
activity of oncogenic Ras in NIH/3T3 cells [27]. It was
subsequently found to potentiate the functions of Ras in some cells
and to antagonize them in others [28]. RAP1A functions in
integrin-mediated adhesion and signaling and in the MAP kinase
cascade [28]. It plays various roles in the proliferation and
differentiation of hematopoietic cells [29]. For example,
megakaryocytic, monocytic, and lymphoid differentiation of cell
lines is associated with RAP1A induction [30,31]. Maturation of
megakaryocytes derived from human cord blood cells is also
associated with induction of RAP1A [32]. Thrombopoietin-
induced megakaryocytic differentiation is mediated by sustained
activation of the ERK/MAPK pathway mediated by RAP1A
activation and inhibition of megakaryocytic differentiation by
stromal contact is associated with a block in RAP1A activation
[31,33]. Finally, RAP1A is activated by erythropoietin [34],
raising the possibility that it plays a role in erythroid
differentiation. Based on these data, the repression of RAP1A
expression by both NUP98-HOXA9 and NUP98-HOXA9/N51S
may play a role in their inhibition of both erythroid and myeloid
differentiation.
PTGS2. This gene was upregulated by NUP98-HOXA9 and
NUP98-HOXA9/N51S. It encodes prostaglandin-endoperoxide
synthase 2 (prostaglandin G/H synthase 2), better known as
cyclooxygenase-2 (COX-2). It is one of two isozymes, COX-1 and
COX-2, that are responsible for the conversion of arachidonic
acid to prostaglandins G2 and H2, which in turn give rise to a
number of different prostaglandins [35]. COX-1 is constitutively
expressed, whereas COX-2 is inducible and is overexpressed in
many tumors resulting in overproduction of prostaglandins,
including PGE2, which appears to play an important role in
Figure 5. Chromatin immunoprecipitation with NUP98-HOXA9
and NUP98-HOXA9/N51S. (A) Schematic drawings of the KBTBD10
and PLN promoters showing transcriptionally active regions identified
in Fig. 4 above. The heavy lines indicate the segments amplified in the
ChIP assay. (B) Chromatin was immunoprecipitated with anti-Flag
antibody from K562 cells nucleofected with either pTracer/CMV-Bsd
vector (control), or vector containing Flag-tagged NUP98-HOXA9 (NH9)
or NUP98-HOXA9/N51S (NH9/N51S). Segments of the KBTBD10 and PLN
promoters (indicated in 5A above) were amplified by PCR. The upper
lanes show immunoprecipitated chromatin (IP) and the lower lanes
show input chromatin (Input).
doi:10.1371/journal.pone.0006719.g005
Figure 6. Retroviral transduction of primary human CD34+
cells. (A) HA-tagged NUP98-HOXA9, NUP98-HOXA9/N51S, HOXA9, or
HOXA9DN open reading frames were subcloned into the MSCV-IRES-
GFP vector. LTR: long terminal repeat; IRES: internal ribosomal entry site;
FG Repeats: NUP98 FG repeat region; HD: HOXA9 homeodomain. (B)
Primary human CD34+ cells were transduced with the retroviral vectors
and sorted for GFP expression; protein expression was verified by
immunoblotting with anti-HA antibody. NH9: NUP98-HOXA9; NH9/
N51S: NUP98-HOXA9/N51S; H9: HOXA9; H9DN: HOXA9DN.
doi:10.1371/journal.pone.0006719.g006
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carcinogenesis [35]. Many types of cancer are known to
overexpress COX-2 and there is a great deal of evidence that
COX-2 inhibition with drugs such as aspirin can be used in the
prevention and treatment of cancer [36]. A number of
hematopoietic malignancies, including chronic myleogenous
leukemia, chronic lymphocytic leukemia, lymphomas, and
myeloma, have been shown to overexpress COX-2, which is
associated with a worse prognosis [37]. There is evidence that the
use of aspirin and other non-steroidal anti-inflammatory drugs
(NSAIDs) is associated with a lower incidence of lymphomas and
acute leukemia [38]. NSAID use has been found to reduce the risk
of AML, particularly the FAB M2 subtype (AML with maturation)
[39], which is the most common subtype in cases with NUP98
gene rearrangements [18]. Our data suggest that the induction of
PTGS2 expression by NUP98-HOXA9 is mediated by the NUP98
moiety and may contribute to the worse prognosis of AML
patients with NUP98 gene rearrangements. It is possible that
COX-2 blockade could help in the treatment of these leukemias.
HEY1. This gene (also known as HERP2) was upregulated by
NUP98-HOXA9 and NUP98-HOXA9/N51S. It is a b-HLH
protein that acts as a transcriptional repressor. It is an important
mediator in the Notch signaling pathway [40] and has been
implicated in the pathogenesis of several types of cancer including
tumors of the brain, lung, pancreas, bone, skin, and kidney
[41,42,43,44,45,46]. Notch signaling is thought to play an
important role in the self-renewal of hematopoietic stem cells
[47] and plays an important role in the pathogenesis of
hematologic malignancies, particularly T-lymphoblastic leukemia
[48]. While the role of Notch signaling in AML is not well
established, these data suggest that upregulation of HEY1 may
contribute to the long-term proliferation and increased numbers of
Figure 7. NUP98-HOXA9 and NUP98-HOXA9/N51S have similar
effects on human CFC morphology. Primary human CD34+ cells
were retrovirally transduced with either control MSCV-IRES-GFP vector
or vector expressing NUP98-HOXA9, NUP98-HOXA9/N51S, HOXA9, or
HOXA9DN, and cells were sorted for GFP positivity. One thousand cells
were seeded into each of two duplicate plates for CFC assay and the
experiment was repeated 3–4 independent times. Representative plates
without magnification (left) and low power photomicrographs of
representative erythroid colonies (right) are shown.
doi:10.1371/journal.pone.0006719.g007
Figure 8. Cell morphology shows homeodomain-independent
disruption of differentiation by NUP98-HOXA9. Cytospin smears
were prepared from CFC plates (see Fig. 7 above) and stained with
Giemsa. Photomicrographs were taken from representative fields with a
606oil objective. For quantitation of the different cell types see Table 1.
B: blast; MM: mature myeloid, IM: intermediate myeloid, ME: mature
erythroid, IE: intermediate erythroid.
doi:10.1371/journal.pone.0006719.g008
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Figure 9. Flow cytometry shows homeodomain-independent disruption of human primary CD34+ cell differentiation by NUP98-
HOXA9. (A) Flow cytometry for erythroid differentiation: Cells from the CFC plates (see Fig. 7 above) were harvested and stained with antibodies to
CD45 and CD235a. The CD235a+ gate was plotted on a histogram (lower panels) to show the expression of CD235a relative to control cells. (B) Flow
cytometry for myeloid differentiation: Cells from the CFC plates (see Fig. 7 above) were harvested and stained with CD45, CD33 and CD11b; the
CD33+ gate was plotted on a histogram to show CD11b expression compared to control (lower panels). The percentages of cells falling within each
gate are shown.
doi:10.1371/journal.pone.0006719.g009
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LTC-ICs induced by NUP98-HOXA9. There is evidence for
involvement of HEY1 in erythroid differentiation: in a mouse cell
line, Notch signaling associated with HEY1 upregulation resulted
in increased the numbers of erythroid cells [49], whereas in
primary human hematopoietic cells upregulation of HEY1 by
JUN was associated with a block in erythroid differentiation [50].
The somewhat different results obtained in these two studies may
reflect the different experimental systems used, but the data
nevertheless suggest that the increased numbers of erythroid cells
and the disrupted erythroid differentiation that we observed in
primary human cells expressing NUP98-HOXA9 or NUP98-
HOXA9/N51S may be mediated at least in part by upregulation
of HEY1.
Discussion
The luciferase reporter and ChIP data in K562 cells
demonstrate at least two modes by which the NUP98-HOXA9
oncogene can dysregulate gene transcription: one that correlates
with DNA-binding through the HOXA9 homeodomain and
another that does not. The data from primary human CD34+ cells
show that the latter mode is necessary and sufficient for most of the
effects of NUP98-HOXA9 on differentiation.
The mechanisms by which NUP98-HOXA9/N51S modulates
gene expression remain to be determined. An isolated NUP98
moiety (NUP98DC) that comprises the FG repeat region of NUP98
caused a mild disruption of myeloid differentiation, but did not have
a significant effect on erythroid differentiation or proliferation (Fig.
S1). This suggests that the FG repeat region may not be entirely
sufficient for the disruption of differentiation. However, nucleoporin
FG repeat regions are inherently disordered [51,52] and it is likely
that NUP98DC would misfold, mislocalize, and/or lose important
protein-protein interactions making the results difficult to interpret.
Based on gene expression analysis, a group of 46 probe sets were
identified that show similar dysregulation by NUP98-HOXA9 and
NUP98-HOXA9/N51S (Fig. 11A and Tables S2–S5) and therefore
presumably do not require direct DNA binding by the homeodo-
main for their dysregulation. Some of these genes are also
dysregulated by HOXA9 and/or HOXA9DN (Fig. 11A), suggest-
ing that their dysregulation is mediated by non-DNA-binding parts
Table 1. Dissection of the effects of NUP98-HOXA9 on hematopoietic differentiation based on cell morphology.
Control NUP98-HOXA9 NUP98-HOXA9/N51S HOXA9 HOXA9DN
Primitive cells % 1.260.9 21.666.4** 5.263.0 7.063.7* 4.761.8
Intermediate erythroid % 2.860.8 16.962.1** 12.166.0 3.963.2 1.560.2
Mature erythroid % 23.767.9 33.8610.2* 45.6611.5* 14.3612.5 6.562.4
Intermediate myeloid % 16.860.7 14.063.3 11.164.0* 33.667.2* 18.163.4
Mature myeloid % 55.666.2 13.763.9** 26.164.7** 41.366.4* 66.466.2
Total cells6106 7.261.3 11.160.7** 9.762.4* 5.063.1 3.460.6
*P,0.05.
**P,0.01.
Averages from 3–4 independent experiments are shown; cells from 2 CFC plates for each experimental condition were harvested. The bottom line shows the average
total cell numbers in the two plates6standard deviations. Cytospins smears were prepared and stained with Giemsa; a 500 cell differential count was performed. Cells
with blast and promyelocyte morphology were counted as primitive; those with myelocyte/metamyelocyte morphology as intermediate myeloid; those with band,
segmented neutrophil, monocyte, and macrophage morphology as mature myeloid; those with intermediate hemoglobinization as intermediate erythroid; and those
with full hemoglobinization as mature erythroid. The first 5 rows show average percentages6standard deviations. The P value was obtained by comparing to control
using a paired two-tailed distribution t-test.
doi:10.1371/journal.pone.0006719.t001
Table 2. Summary of the effects of NUP98-HOXA9, NUP98-HOXA9/N51S, HOXA9, and HOXA9DN on the differentiation and
proliferation of primary human CD34+ cells.
NUP98-HOXA9 NUP98-HOXA9/N51S HOXA9 HOXA9DN
Erythroid differentiation
Morphologic maturity QQQ Q NC NC
CD235a QQ QQ NC NC
Erythroid cell No. qq qq NC NC
Myeloid differentiation
Morphologic maturity QQ Q Q NC
CD11b QQ QQ NC NC
Myeloid cell No. QQ QQ NC NC
Proliferation
Liquid culture qqq q q NC
LTC-IC qq Q NC NC
CFC cell number qq q NC NC
NC indicates no change.
doi:10.1371/journal.pone.0006719.t002
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of the homeodomain such as those that mediate dimerization with
other proteins [53]. One possibility is that the homeodomain would
interact with promoters indirectly by dimerizing with another DNA-
binding factor. Such indirect binding may be difficult to detect with
our ChIP assays and cannot be entirely excluded as a mechanism
for the transactivation of the PLN promoter. Another possibility is
that the homeodomain may disrupt transcription by titrating away
transcription factors through dimerization. The remaining 26
probes represent 23 genes that appear to be homeodomain-
independent (Fig. 11A) and their dysregulation requires the NUP98
moiety of NUP98-HOXA9. Based on the functions of the NUP98
moiety, an intriguing possibility is that expression of these genes may
be dysregulated by a disruption in nucleocytoplasmic transport. The
NUP98 portion of NUP98 fusions contains most or all of its FG
repeats, which interact with nuclear transport carriers that mediate
the nucleocytoplasmic transport of proteins [54,55,56]. It also
contains the GLEBS motif that plays a role in RNA export by
interacting with the mRNA export factor RAE1 [57]. Therefore
homeodomain-independent functions of NUP98-HOXA9 (and
other NUP98 fusions) may be mediated by disruption of the
nucleocytoplasmic transport of transcription factors or RNAs that
are important in myeloid differentiation and proliferation. Future
experiments directed at identifying proteins that interact with
NUP98-HOXA9 and examining its effects on nucleocytoplasmic
transport may elucidate the homeodomain-independent mecha-
nisms that contribute to the leukemogenic functions of NUP98
fusion proteins.
Figure 10. The two moieties of NUP98-HOXA9 synergistically
increase proliferation of primary human CD34+ cells. Primary
human CD34+ cells were retrovirally transduced with either control
MSCV-IRES-GFP vector or vector expressing NUP98-HOXA9 (NH9),
NUP98-HOXA9/N51S (NH9/N51S), HOXA9 (H9), or HOXA9DN (H9DN),
and cells were sorted for GFP positivity. (A) The cumulative fold
increase in cell numbers compared to day 0 is plotted on a logarithmic
scale against time. The experiment was repeated 3 times; results from a
representative experiment are shown. (B) LTC-IC assay showing the
average fold change compared to control from 3 independent
experiments. The error bars represent standard deviations.
doi:10.1371/journal.pone.0006719.g010
Figure 11. Homeodomain-independent gene regulation by
NUP98-HOXA9 in primary human CD34+ cells. (A) Primary
human CD34+ cells were retrovirally transduced with either control
MSCV-IRES-GFP vector or vector expressing NUP98-HOXA9 (NH9),
NUP98-HOXA9/N51S (NH9/N51S), HOXA9 (H9), or HOXA9DN (H9DN).
Cells were sorted for GFP positivity and total RNA was subjected to
microarray analysis. The experiment was performed two independent
times and only genes that showed up- or down-regulation by 1.74 fold
or more compared to control in both experiments were considered
dysregulated. As shown in the upper Venn diagram, 46 probe sets
showed dysregulation by both NUP98-HOXA9 (NH9) and NUP98-
HOXA9/N51S (NH9/N51S). Of these, 26 did not show dysregulation by
either HOXA9DN (H9DN) or HOXA9 (H9) and were considered
homeodomain-independent (lower Venn diagram). These 26 probe
sets represent 23 unique genes listed on the left. Genes with a potential
role in homeodomain-independent transforming functions of NUP98-
HOXA9 are highlighted in red and are discussed in the text. (B)
Chromatin was immunoprecipitated with anti-Flag antibody from K562
cells nucleofected with either pTracer/CMV-Bsd vector (control), or
vector containing Flag-tagged NUP98-HOXA9 (NH9) or NUP98-HOXA9/
N51S (NH9/N51S). A segment of the HEY1 promoter was amplified by
PCR (see Materials and Methods for primer sequences). The upper lanes
show immunoprecipitated chromatin (IP) and the lower lanes show
input chromatin (Input).
doi:10.1371/journal.pone.0006719.g011
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We also report here for the first time the effects of wild-type
HOXA9 on primary human hematopoietic cells. HOXA9 is
leukemogenic in mice, and it causes proliferation and blocks
differentiation in primary mouse hematopoietic cells in vitro
[12,17]. While wild-type HOXA9 is overexpressed in a subset of
human AML [58,59,60,61], its effects on primary human
hematopoietic cell differentiation and proliferation have not
been previously reported, and its contribution to human
myeloid leukemogenesis is not clear. In contrast to findings in
mice, our data show that HOXA9 has modest effects on the
proliferation and differentiation of primary human CD34+ cells.
It causes a mild increase in the numbers of cells in long-term
liquid culture and a mild block in myeloid maturation that is
best appreciated on morphologic examination of Giemsa-
stained cells (Tables 1 and 2). Microarray analysis of primary
human CD34+ cells shows that HOXA9 dysregulates genes
recognized by 659 probe sets compared to only 203 for NUP98-
HOXA9/N51S (Fig. 11). It is therefore remarkable that
NUP98-HOXA9/N51S causes a much more pronounced
disruption of differentiation than HOXA9.
It is of interest to note that different differentiation markers did
not give identical estimates of the extent of differentiation in our
samples. For example, HOXA9 expression clearly decreased the
numbers of mature myeloid cells and increased the numbers of less
mature myeloid cells as judged by morphologic examination of
Giemsa-stained Cytospin smears (Fig. 8 and Table 1). These
findings are consistent with a block in myeloid maturation; yet flow
cytometry did not reveal a significant difference in the expression
of CD11b between HOXA9-expressing cells and controls (Fig. 9B).
On the other hand, cells expressing NUP98-HOXA9/N51S did
not show morphologic evidence of erythroid immaturity in
Giemsa-stained preparations (Fig. 8 and Table 1); yet a clear
block in erythroid differentiation was observed by flow cytometry
as evidenced by decreased expression of CD235a (Fig. 9A). Thus,
a combination of morphology and immunophenotyping can
uncover subtle defects in hematopoietic differentiation that may
not be otherwise obvious.
Materials and Methods
Plasmid construction
The pTracer-CMV/Bsd construct expressing HA-tagged
NUP98-HOXA9 was previously described [15]. The N51S
mutation was created in this construct by replacing a BglII/XbaI
fragment with a synthetic fragment containing an A to G
substitution in the 51st codon of the homeodomain. The mutation
was confirmed by sequencing. MSCV-IRES-GFP constructs
expressing HA-tagged NUP98-HOXA9, and HOXA9 have been
described [6]. NUP98-HOXA9/N51S and HOXA9DN [4] were
subcloned upstream of IRES into MSCV-IRES-GFP. For luciferase
constructs, the following promoter regions were amplified from
human genomic DNA (Roche, Basel, Switzerland) by PCR using
PfuUltra high-fidelity DNA polymerase (Stratagene, La Jolla, CA,
USA): HOXB6 from 21934 to +81; JUN from 22013 to +89;
KBTBD10 from 22369 to +76; PLN from 21937 to +81; and
SERPINE1 from22012 to +74. PCR products were subcloned into
pGL4.11 (Promega, Madison, WI, USA) upstream of the luciferase
gene using the NheI/EcoRV sites for HOXB6, JUN, and KBTBD10
promoters; the KpnI/XhoI sites for the PLN promoter; and the XhoI/
EcoRV sites for SERPINE1 promoter. Deletions of the KBTBD10
and PLN promoters are shown in Fig. 4A and 4B; they were
similarly subcloned into pGL4.11. All sequences generated by PCR
were confirmed by DNA sequencing.
Retrovirus production
NUP98-HOXA9 retrovirus was previously described [15]. For
the remaining retroviruses, GP293 cells were transiently trans-
fected with 4.4 mg of retroviral vector and 1.1 mg of pVSV-G
expression vector using Lipofectamine Plus reagent (Invitrogen,
Carlsbad, CA, USA). After 48 h, the culture supernatant,
containing VSV-pseudotyped retrovirus, was collected and used
for transduction of PG13 packaging cells by spinoculation in the
presence of 8 mg/mL polybrene (Hexadimethrine Bromide;
Sigma-Aldrich Corp., St. Louis, MO, USA). The PG13 culture
supernatant containing GaLV-pseudotyped retrovirus was used for
transduction of CD34+ primary cells.
Retroviral transduction and analysis of primary human
CD34+ cells
Frozen human CD34+ cells purified from mobilized peripheral
blood of two healthy volunteers were obtained from StemCell
Technologies (Vancouver, British Columbia, Canada) and the
Fred Hutchinson Cancer Research Center (Seattle, WA, USA);
and of a deceased autologous transplant donor through the Bone
Marrow Transplant Laboratory at Northwestern Memorial
Hospital after Institutional Review Board approval. Cells were
prestimulated and transduced with retrovirus as described [15].
After 46 h, GFP positive cells were isolated using a MoFlo high-
speed sorter (Dako, Glostrup, Denmark) and expression of the
transfected gene was confirmed by immunoblotting with anti-HA
tag antibody. Long-term liquid culture of primary cells was
performed in the presence of a cytokine cocktail as previously
described [15]. Colony-forming cell (CFC) and long-term culture-
initiating cell (LTC-IC) assays were performed as previously
described [15]. Cytospin preparations of cells harvested from the
CFC plates were stained with Giemsa and a 500-cell differential
count was performed using an Olympus BX51 microscope
(Olympus America, Center Valley, PA, USA). Cells with blast
and promyelocyte morphology were counted as primitive; those
with myelocyte/metamyelocyte morphology as intermediate
myeloid; those with band, segmented neutrophil, monocyte, and
macrophage morphology as mature myeloid; those with interme-
diate hemoglobinization as intermediate erythroid; and those with
full hemoglobinization as mature erythroid. Photomicrographs
were taken with an Olympus DP71 camera with a 606oil
objective.
Flow cytometry
Flow cytometry was performed on a FACScan flow cytometer
(BD Biosciences, San Jose, CA, USA) upgraded to 5 colors and
two lasers, and analyzed using FCS3 Express (De Novo Software,
Thornhill, Ontario, Canada) and FlowJO v8.6.3 (Tree Star, Inc.,
Ashland, OR) software. The antibodies used for these studies were
CD11b (phycoerythrin-conjugated clone ICRF44) from
eBioscience (San Diego, CA, USA); CD235a (allophycocyanin-
conjugated clone GA-R2) from BD (Franklin Lakes, NJ, USA);
and CD33 (allophycocyanin-conjugated clone D3HL60.251) and
CD45 (phycoerythrin-Cy7-conjugated clone J.33) from Beckman
Coulter (Miami, FL, USA).
Microarray analysis of primary human CD34+ cells
Sorted GFP-positive cells were snap-frozen 3 days after
transduction and submitted to the Siteman Cancer Center
Laboratory for Clinical Genomics where total RNA was isolated
and target preparation and microarray hybridization were
performed. Labeled targets were hybridized to Affymetrix HG-
U133 Plus 2.0 GeneChip microarrays. Data were merged with the
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updated gene annotation data for each probe set on the array
using Spotfire DecisionSite 9.1.1 for Functional Genomics (Spot-
fire, Somerville, MA). Probe sets were filtered according to
present/absent calls and the sets that were absent across all chips
were filtered from the analysis. The fold change of each probe set
was calculated by dividing the absolute signal intensity from
NUP98-HOXA9, NUP98-HOXA9/N51S, HOXA9, and HOX-
A9DN samples by that of the control sample (vector only). Probes
scored as increasing and absent in the numerator, and those scored
as decreasing and absent in the denominator were also filtered out.
The experiment was performed 2 independent times. Probe sets
induced or repressed by 1.74-fold or greater in both experiments
were considered differentially expressed. Gene intersection lists
were generated using Spotfire DecisionSite 9.1.1 for Functional
Genomics. All microarray data reported in the manuscript are
described in accordance with MIAME guidelines.
Luciferase assay
Cells were transfected by electroporation using a Bio-Rad
GenePulser with 10 mg pGL4.11 vector or pGL4.11 driven by the
indicated promoters and 20 mg of either empty pTracer-CMV/
Bsd vector, or vector expressing HA-tagged NUP98-HOXA9 or
NUP98-HOXA9/N51S. To control for efficiency of transfection,
0.5 mg of pRL-TK (Promega), which expresses Renilla luciferase,
was included. Ten million cells were incubated with the DNA for
10 min at room temperature (RT) before electroporation and
10 min after electroporation, and were cultured in 20 mL IMDM
media with 10% FBS, 2 mM L-glutamine, and 100 units/mL
pencillin/streptomycin. Luciferase activity was measured 48 h
after electroporation using the Dual Luciferase Reporter Assay
System (Promega) and the results were normalized to Renilla
luciferase.
Chromatin Immunoprecipitation
K562 (107) cells were nucleofected using a Nucleofector device
(Lonza, Cologne, Germany) with either empty pTracer-CMV/Bsd
vector or vector containing Flag-tagged NUP98-HOXA9 or
NUP98-HOXA9/N51S and collected after 12 h. After cross-
linking with 1% formaldehyde and quenching with 0.375 M
glycine, cells were washed twice with ice-cold TBS. Nuclei were
isolated by washing with 10 mM Tris-HCl, pH 7.5, 10 mM NaCl,
3 mM MgCl2, 0.5% NP-40 three times and were freeze-thawed.
Nuclei were lysed by adding 200 mL of micrococcal nuclease
buffer (10 mM Tris-HCl, pH 7.5, 200 mM NaCl, 3 mM MgCl2,
1 mM CaCl2, 4% NP-40, 3 mM EGTA, 1% SDS) and 1 mL FA
lysis buffer (50 mM HEPES-NaOH, pH 7.5, 150 mM NaCl,
1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate,
0.1% SDS) with 2 mM PMSF and complete protease inhibitor
cocktail (Roche). The lysate was sonicated and centrifuged at
17,0006g for 30 min at 4uC. The supernatant was precleared with
Sepharose 4B beads (GE Healthcare, Piscataway, NJ, USA) for
2 h at 4uC and incubated with anti-Flag agarose M2 antibody
(Sigma) overnight at 4uC. The beads were washed twice with FA
lysis buffer, once with of FA lysis buffer with 500 mM NaCl, once
with ChIP wash buffer (10 mM Tris-HCl, pH 7.5, 0.25 M LiCl,
1 mM EDTA, 0.5% NP-40, 0.5% sodium deoxycholate), and
once with TE (10 mM Tris-HCl pH 7.5, 1 mM EDTA). The
beads were eluted twice at 65uC for 10 min with a total of 250 mL
of 1% SDS in TE. After adding 250 ml TE and 100 mg proteinase
K, the eluate was incubated at 37uC for 2 h. Crosslinks were
reversed at 65uC overnight followed by phenol chloroform
extraction and DNA precipitation with 100 mL 4M LiCl and
1 mL ethanol. KBTBD10, PLN, and HEY1 promoter regions were
amplified by PCR (35 cycles) using the following primer pairs:
KBTBD10:
Forward: 59CACATCTCATATTCTTGACCTTTGC39
Reverse: 59CTGGAACTTTTAATCACTAGGGAAAC39
PLN (1):
Forward: 59CCATAAAGTTGCCCTTAATACTGC39
Reverse: 59CTTGTGTGTATGGGAGAAGG39
PLN (2):
Forward: 59CCCGGCTTTACAAAAAAATTATTTCC39
Reverse: 59CACCCCCAAAATAGCAATATGC39
PLN (3):
Forward: 59CAAATGATTTGCTCTAGAGATGGATTTTC39
Reverse: 59CGGGCATCATTCTCCTC39
HEY1:
Forward: 59TCACGTGGCACCCAGTACAC39
Reverse: 59GCATCTCATTTCCGGGGAAG39
PCR products were resolved on 2% agarose gels and imaged
with a Chemidoc XRS system (Bio-Rad).
Supporting Information
Table S1 Early NUP98-HOXA9 target genes in K562 cells
identified by microarray analysis. K562 cells were nucleofected
with either control pTracer-CMV/Bsd plasmid or with plasmid
expressing NUP98-HOXA9 followed by sorting for GFP expres-
sion. Cells were harvested 8 h after nucleofection and RNA was
subjected to microarray analysis using Affymetrix HG-U133 Plus
2.0 GeneChip microarrays. The experiment was performed 2
independent times and genes showing 2-fold or higher dysregu-
lation compared to control in both experiments are listed in the
table. The fold change shown is the average of the 2 experiments.
In cases where more than one probe corresponds to the same
gene, the number shown represents the average fold change shown
by all the probes representing that gene in the two experiments.
Dysregulation of several genes was confirmed by quantitative RT-
PCR. Reverse transcription was performed with the SuperScript
III kit (Invitrogen), according to the manufacturer’s protocol.
Quantitative RT-PCR was performed using the GeneAmp 5700
sequence Detection System using iQ SYBR Green Supermix (Bio
Rad). The signal intensities were normalized against glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH); the numbers shown
represent fold change compared to control.
Found at: doi:10.1371/journal.pone.0006719.s001 (0.01 MB
PDF)
Table S2 Genes dysregulated by NUP98-HOXA9. Primary
human CD34+ cells were retrovirally transduced with either
control MSCV-IRES-GFP vector or vector expressing NUP98-
HOXA9. Cells were sorted for GFP positivity and total RNA was
subjected to microarray analysis. The experiment was performed
two independent times and only genes that showed up- or down-
regulation by 1.74 fold or more compared to control in both
experiments were considered dysregulated.
Found at: doi:10.1371/journal.pone.0006719.s002 (0.07 MB
PDF)
Table S3 Genes dysregulated by NUP98-HOXA9/N51S.
Primary human CD34+ cells were retrovirally transduced with
either control MSCV-IRES-GFP vector or vector expressing
NUP98-HOXA9/N51S. Cells were sorted for GFP positivity and
total RNA was subjected to microarray analysis. The experiment
was performed two independent times and only genes that showed
up- or down-regulation by 1.74 fold or more compared to control
in both experiments were considered dysregulated.
Found at: doi:10.1371/journal.pone.0006719.s003 (0.02 MB
PDF)
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Table S4 Genes dysregulated by wild-type HOXA9. Primary
human CD34+ cells were retrovirally transduced with either
control MSCV-IRES-GFP vector or vector expressing wild-type
HOXA9. Cells were sorted for GFP positivity and total RNA was
subjected to microarray analysis. The experiment was performed
two independent times and only genes that showed up- or down-
regulation by 1.74 fold or more compared to control in both
experiments were considered dysregulated.
Found at: doi:10.1371/journal.pone.0006719.s004 (0.06 MB
PDF)
Table S5 Genes dysregulated by HOXA9DN. Primary human
CD34+ cells were retrovirally transduced with either control
MSCV-IRES-GFP vector or vector expressing HOXA9DN. Cells
were sorted for GFP positivity and total RNA was subjected to
microarray analysis. The experiment was performed two inde-
pendent times and only genes that showed up- or down-regulation
by 1.74 fold or more compared to control in both experiments
were considered dysregulated.
Found at: doi:10.1371/journal.pone.0006719.s005 (0.03 MB
PDF)
Figure S1 The FG repeat region of NUP98-HOXA9 has a
partial effect on differentiation. The NUP98 portion of NUP98-
HOXA9 (NUP98DC) was subcloned into the MSCV-IRES-GFP
vector. Primary human CD34+ cells were retrovirally transduced
with either control MSCV-IRES-GFP vector or vector expressing
NUP98DC, and were sorted for GFP positivity. (A) Flow
cytometry for myeloid differentiation: Cells from CFC plates were
harvested and stained with CD45, CD33 and CD11b; the CD33+
gate was plotted on a histogram to show CD11b expression
compared to control (lower panel). The data show a mild decrease
in the number of myeloid cells with shift to immaturity in cells
expressing NUP98DC. (B) Flow cytometry for erythroid differen-
tiation: Cells from CFC plates were harvested and stained with
antibodies to CD45 and CD235a. The CD235a+ gate was plotted
on a histogram (lower panel) to show the expression of CD235a
relative to control cells. (C) Sorted cells were grown in liquid
culture in the presence of cytokines and the cumulative fold
increase in cell numbers compared to day 0 is plotted on a
logarithmic scale against time.
Found at: doi:10.1371/journal.pone.0006719.s006 (0.88 MB TIF)
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